Semiautomated platform makes consistent batches of extracellular vesicles
โฎ BeforeProducing extracellular vesicles consistently at pharmaceutical quality was difficult.
โ
NowA validated semiautomated platform now produces batches that meet pharmaceutical quality requirements.
In short
- A study led by IGTP and the Blood and Tissue Bank developed the manufacturing platform.
- The platform meets pharmaceutical quality requirements for extracellular vesicles.
- The team describes the work as a key step toward clinical application.
Why it's good news
Extracellular vesicles are tiny particles that cells release, and they are studied as possible regenerative therapies. Making them reliably enough for medicine has been a major obstacle. This platform has been shown to meet pharmaceutical quality standards, which is a prerequisite for clinical use. Clinical use is still ahead, so the step is toward treatments rather than a treatment itself.
Advertisement
From Phys.org
A study led by researchers from the Germans Trias i Pujol Research Institute (IGTP) and the Blood and Tissue Bank (BST) has developed and validated a manufacturing platform for extracellular vesicles that meets pharmaceutical quality requirements, marking a key step toward their clinical application.
Ask this story
More like this
Advertisement